Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

Movement Disorders

Volumn 21, Issue 6, 2006, Pages 839-846

  Gomez Ramirez, Jordi ^a   Johnston, Tom H ^a   Visanji, Naomi P ^a   Fox, Susan H ^b   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Histamine H3 receptor agonist; L dopa induced dyskinesia; MPTP lesioned marmoset; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; BENSERAZIDE PLUS LEVODOPA; GLUTAMIC ACID; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; IMETIT; IMMEPIP; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CHOREA; CONTROLLED STUDY; CORPUS STRIATUM; DISABILITY; DRUG ACTIVITY; DRUG INDUCED DISEASE; DYSKINESIA; DYSTONIA; FEMALE; MARMOSET; MONOTHERAPY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CALLITHRIX; CHOREA; DISEASE MODELS, ANIMAL; FEMALE; HISTAMINE AGONISTS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, HISTAMINE H3;

EID: 33745835791     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20828     Document Type: Article

References (57)

1. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 2001;124(Pt. 11):2131-2146.
2. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23(Suppl. 10):S8-S19.
3. Sharpe JA, Rewcastle NB, Lloyd KG, Hornykiewicz O, Hill M, Tasker RR. Striatonigral degeneration: response to levodopa therapy with pathological and neurochemical correlation. J Neurol Sci 1973;19:275-286.
4. Hornykiewicz O. The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease. Wien Klin Wochenschr 1963;75:309-312.
5. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005;112:359-391.
6. Weiss JL, Ng LK, Chase TN. Long-lasting dyskinesia induced by levodopa. Lancet 1971;1:1016-1017.
7. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21: 343-354.
8. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23(Suppl. 10):S109-S115.
9. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26.
10. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
11. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999;290:1034-1040.
12. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802.
13. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute doubleblind placebo-controlled study. Mov Disord 2001;16:515-520.
14. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-1386.
15. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
16. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Invest Drugs 2004;5:720-726.
17. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876.
18. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302:832-837.
19. Molina-Hernandez A, Nunez A, Sierra JJ, Arias-Montano JA. Histamine H3 receptor activation inhibits glutamate release from rat striatal synaptosomes. Neuropharmacology 2001;41:928-934.
20. Doreulee N, Yanovsky Y, Flagmeyer I, Stevens DR, Haas HL, Brown RE. Histamine H(3) receptors depress synaptic transmission in the corticostriatal pathway. Neuropharmacology 2001;40: 106-113.
21. Arias-Montano JA, Floran B, Garcia M, Aceves J, Young JM. Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(l) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices. Br J Pharmacol 2001;133:165-171.
22. Molina-Hernandez A, Nunez A, Arias-Montano JA. Histamine H13-receptor activation inhibits dopamine synthesis in rat striatum. Neuroreport 2000;11:163-166.
23. Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999;55:1101-1107.
24. Clark EA, Hill SJ. Sensitivity of histamine H3 receptor agonist-stimulated [35S]GTP gamma[S] binding to pertussis toxin. Eur J Pharmacol 1996;296:223-225.
25. Takeshita Y, Watanabe T, Sakata T, Munakata M, Ishibashi H, Akaike N. Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus. Neuroscience 1998;87:797-805.
26. Gomez-Ramirez J, Ortiz J, Blanco I. Presynaptic H3 autoreceptors modulate histamine synthesis through cAMP pathway. Mol Pharmacol 2002;61:239-245.
27. Torrent A, Moreno-Delgado D, Gomez-Ramirez J, et al. H3 autoreceptors modulate histamine synthesis through calcium/calmodulin- and cAMP-dependent protein kinase pathways. Mol Pharmacol 2005;67:195-203.
28. Prast H, Tran MH, Fischer H, et al. Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;360:558-564.
29. Sanchez-Lemus E, Arias-Montano JA. Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices. Neurosci Lett 2004;364:179-184.
30. Pillot C, Ortiz J, Heron A, Ridray S, Schwartz JC, Arrang JM. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J Neurosci 2002;22:7272-7280.
31. Pillot C, Heron A, Cochois V, et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002; 114:173-193.
32. Garcia M, Floran B, Arias-Montano JA, Young JM, Aceves J. Histamine H3 receptor activation selectively inhibits doparnine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata. Neuroscience 1997;80:241-249.
33. Threlfell S, Cragg SJ, Kallo I, Turi GF, Coen CW, Greenfield SA. Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata. J Neurosci 2004;24:8704-8710.
34. Garbarg M, Arrang JM, Rouleau A, et al. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J Pharmacol Exp Ther 1992;263:304-310.
35. Coruzzi G, Gambarelli E, Bertaccini G, Timmerman H. Cardiovascular effects of selective agonists and antagonists of histamine H3 receptors in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1995;351:569-575.
36. Jenner P, Rose S, Nomoto M, Marsden CD. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects. Adv Neurol 1987;45:183-186.
37. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999; 14:744-753.
38. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002;17:1180-1187.
39. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-241.
40. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-dopa-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-dopa in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2004;188:471-479.
41. Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Milan MJ, Brotchie JM. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 2004;188: 128-138.
42. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001;16:642-650.
43. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18:872-883.
44. Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003;18:1301-1305.
45. Hill MP, Ravenscroft P, Bezard E, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004;310: 386-394.
46. Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000;47(4 Suppl. 1):S60-S68.
47. Ochi M, Shiozaki S, Kase H. L-dopa-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease. Synapse 2004;52:163-165.
48. Ochi M, Shiozaki S, Kase H. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience 2004;127:223-231.
49. Anichtchik OV, Rinne JO, Kalimo H, Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol 2000;163:20-30.
50. Anichtchik OV, Huotari M, Peitsaro, N, Haycock JW, Mannisto PT, Panula P. Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Eur J Neurosci 2000;12:3823-3832.
51. Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H, Panula P. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis 2001;8:707-716.
52. Rinne JO, Anichtchik OV, Eriksson KS, et al. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J Neurochem 2002;81:954-960.
53. Ryu JH, Yanai K, Watanabe T. Marked increase in histamine H3 receptors in the striatum and substantia nigra after 6-hydroxydopamine-induced denervation of dopaminergic neurons: an autoradiographic study. Neurosci Lett 1994;178:19-22.
54. Lamberty Y, Margineanu DG, Dassesse D, Klitgaard H. H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. Pharmacol Res 2003;48:193-198.
55. Arrang JM, Garbarg M, Lancelot JC, et al. Highly potent and selective ligands for histamine H3-receptors. Nature 1987;327: 117-123.
56. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003;183: 458-468.
57. van der Stelt M, Fox SH, Hill M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 2005;19:1140-1142.